Novel agents for chronic lymphocytic leukemia
Open Access
- 16 May 2013
- journal article
- review article
- Published by Springer Nature in Journal of Hematology & Oncology
- Vol. 6 (1) , 36
Abstract
Chronic lymphocytic leukemia (CLL) is a heterogeneous group of B-cell neoplasm. CLL is typically sensitive to a variety of cytotoxic agents, but relapse frequently occurs with conventional approaches. The treatment of CLL is evolving rapidly with the introduction of novel drugs, such as bendamustine, ofatumumab, lenalidomide, ibrutinib, idelalisib, veltuzumab, XmAb5574, navitoclax, dasatinib, alvespimycin, and TRU-016. This review summarizes the most current clinical experiences with these agents in the treatment of CLL.Keywords
This publication has 52 references indexed in Scilit:
- Polo-like kinase 1 as target for cancer therapyExperimental Hematology & Oncology, 2012
- CD19: a biomarker for B cell development, lymphoma diagnosis and therapyExperimental Hematology & Oncology, 2012
- Novel CD20 monoclonal antibodies for lymphoma therapyJournal of Hematology & Oncology, 2012
- Therapeutic advancement of chronic lymphocytic leukemiaJournal of Hematology & Oncology, 2012
- MicroRNAs in B cell development and malignancyJournal of Hematology & Oncology, 2012
- The Four types of Tregs in malignant lymphomasJournal of Hematology & Oncology, 2011
- CD19 targeting of chronic lymphocytic leukemia with a novel Fc-domain–engineered monoclonal antibodyBlood, 2010
- Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia: a report from the International Workshop on Chronic Lymphocytic Leukemia updating the National Cancer Institute–Working Group 1996 guidelinesBlood, 2008
- Targeting CD37-positive lymphoid malignancies with a novel engineered small modular immunopharmaceuticalBlood, 2007
- Bruton tyrosine kinase is essential for botrocetin/VWF-induced signaling and GPIb-dependent thrombus formation in vivoBlood, 2006